BRD7 plays an anti-inflammatory role during early acute inflammation by inhibiting activation of the NF-κB signaling pathway

Cellular and Molecular Immunology

Volumn 14, Issue 10, 2017, Pages 830-841

  Zhao, Ran ^a,b,c   Liu, Yukun ^b,c   Wang, Heran ^b,c   Yang, Jing ^b,c   Niu, Weihong ^b,c   Fan, Songqing ^d   Xiong, Wei ^b,c   Ma, Jian ^b,c   Li, Xiaoling ^b,c   Phillips, Joshua B ^e   Tan, Ming ^e   Qiu, Yuanzheng ^a   Li, Guiyuan ^b,c   Zhou, Ming ^a,b,c  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^d CENTRAL SOUTH UNIVERSITY   (China)

^e UNIVERSITY OF SOUTH ALABAMA   (United States)

Author keywords

acute inflammation; BRD7; DSS; LPS; NF B pathway

Indexed keywords

BROMODOMAIN CONTAINING PROTEIN 7; CXCL1 CHEMOKINE; DEXTRAN SULFATE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MEMBRANE PROTEIN; MESSENGER RNA; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; BRD7 PROTEIN, MOUSE; CXCL1 PROTEIN, MOUSE; NONHISTONE PROTEIN; NOS2 PROTEIN, MOUSE; RELA PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL NUCLEUS; CONTROLLED STUDY; CYTOPLASM; DEXTRAN SULFATE SODIUM-INDUCED COLITIS; DISEASE ACTIVITY SCORE; EMBRYO; FEMALE; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MALE; MOUSE; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; ANIMAL; C57BL MOUSE; CELL CULTURE; CHEMICALLY INDUCED; COLITIS; FIBROBLAST; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; METABOLISM;

ANIMALS; CELLS, CULTURED; CHEMOKINE CXCL1; CHROMOSOMAL PROTEINS, NON-HISTONE; COLITIS; DEXTRAN SULFATE; FIBROBLASTS; INFLAMMATION; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NITRIC OXIDE SYNTHASE TYPE II; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85014746135     PISSN: 16727681     EISSN: None     Source Type: Journal    
DOI: 10.1038/cmi.2016.31     Document Type: Article

References (54)

1. Peng C, Liu HY, Zhou M, Zhang LM, Li XL, Shen SR et al. BRD7 suppresses the growth of nasopharyngeal carcinoma cells (HNE1) through negatively regulating beta-catenin and ERK pathways. Mol Cell Biochem 2007; 303: 141-149.
2. Zhou J, Ma J, Zhang BC, Li XL, Shen SR, Zhu SG et al. BRD7, a novel bromodomain gene, inhibits G1-S progression by transcriptionally regulating some important molecules involved in ras/MEK/ERK and Rb/E2F pathways. J Cell Physiol 2004; 200: 89-98.
3. Hu K, Liao D, Wu W, Han AJ, Shi HJ, Wang F et al. Targeting the anaphase-promoting complex/cyclosome (APC/C)-bromodomain containing 7 (BRD7) pathway for human osteosarcoma. Oncotarget 2014; 5: 3088-3100.
4. Park YA, Lee JW, Kim HS, Lee YY, Kim TJ, Choi CH et al. Tumor suppressive effects of bromodomain-containing protein 7 (BRD7) in epithelial ovarian carcinoma. Clin Cancer Res 2014; 20: 565-575.
5. Zhou M, Peng C, Nie XM, Zhang BC, Zhu SG, Yu Y et al. [Expression of BRD7-interacting proteins,BRD2 and BRD3, in nasopharyngeal carcinoma tissues]. Ai Zheng 2003; 22: 123-127.
6. Berkovits BD, Wang L, Guarnieri P, Wolgemuth DJ. The testis-specific double bromodomain-containing protein BRDT forms a complex with multiple spliceosome components and is required for mRNA splicing and 3′-UTR truncation in round spermatids. Nucleic Acids Res 2012; 40: 7162-7175.
7. Picaud S, Strocchia M, Terracciano S, Lauro G, Mendez J, Daniels DL et al. 9H-purine scaffold reveals induced-fit pocket plasticity of the BRD9 bromodomain. J Med Chem 2015; 58: 2718-2736.
8. Sun H, Liu J, Zhang J, Shen W, Huang H, Xu C et al. Solution structure of BRD7 bromodomain and its interaction with acetylated peptides from histone H3 and H4. Biochem Biophys Res Commun 2007; 358: 435-441.
9. Zhou M, Liu H, Xu X, Zhou H, Li X, Peng C et al. Identification of nuclear localization signal that governs nuclear import of BRD7 and its essential roles in inhibiting cell cycle progression. J Cell Biochem 2006; 98: 920-930.
10. Kaeser MD, Aslanian A, Dong MQ, Yates JR, Emerson BM. BRD7, a novel PBAF-specific SWI/SNF subunit, is required for target gene activation and repression in embryonic stem cells. J Biol Chem 2008; 283: 32254-32263.
11. Hugo HJ, Saunders C, Ramsay RG, Thompson EW. New insights on COX-2 in chronic inflammation driving breast cancer growth and metastasis. J Mammary Gland Biol Neoplasia 2015; e-pub ahead of print 21 July 2015; doi:10.1007/s10911-015-9333-4.
12. Ma X, Aoki T, Tsuruyama T, Narumiya S. Definition of prostaglandin E2-EP2 Signals in the colon tumor microenvironment that amplify inflammation and tumor growth. Cancer Res 2015; 75: 2822-2832.
13. Fernandes JV, Cobucci RN, Jatoba CA, de Medeiros FT, de Azevedo JW, de Araujo JM. The role of the mediators of inflammation in cancer development. Pathol Oncol Res 2015; 21: 527-534.
14. Dong ZW, Ren CG, Xia Y, Su D, Du TT, Fan HB et al. Pten regulates homeostasis and inflammation-induced migration of myelocytes in zebrafish. J Hematol Oncol 2014; 7: 17.
15. Cooks T, Harris CC, Oren M. Caught in the cross fire: p53 in inflammation. Carcinogenesis 2014; 35: 1680-1690.
16. Schmid T, Bajer MM, Blees JS, Eifler LK, Milke L, Rubsamen D et al. Inflammation-induced loss of Pdcd4 is mediated by phosphorylationdependent degradation. Carcinogenesis 2011; 32: 1427-1433.
17. Xu Y, Cao W, Zhou M, Li C, Luo Y, Wang H et al. Inactivation of BRD7 results in impaired cognitive behavior and reduced synaptic plasticity of the medial prefrontal cortex. Behav Brain Res 2015; 286: 1-10.
18. Wang H, Zhao R, Guo C, Jiang S, Yang J, Xu Y et al. Knockout of BRD7 results in impaired spermatogenesis and male infertility. Sci Rep 2016; 6: 21776.
19. Tominaga K, Kirikae T, Nakano M. Lipopolysaccharide (LPS)-induced IL-6 production by embryonic fibroblasts isolated and cloned from LPS-responsive and LPS-hyporesponsive mice. Mol Immunol 1997; 34: 1147-1156.
20. Ren T, Tian T, Feng X, Ye S, Wang H, Wu W et al. An adenosine A3 receptor agonist inhibits DSS-induced colitis in mice through modulation of the NF-kappaB signaling pathway. Sci Rep 2015; 5: 9047.
21. Wirtz S, Neufert C, Weigmann B, Neurath MF. Chemically induced mouse models of intestinal inflammation. Nat Protoc 2007; 2: 541-546.
22. Cooper HS, Murthy SN, Shah RS, Sedergran DJ. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest 1993; 69: 238-249.
23. Rani P, Pal D, Hegde RR, Hashim SR. Acetamides: chemotherapeutic agents for inflammation-associated cancers. J Chemother 2015; e-pub ahead of print 21 July 2015; doi:10.1179/19739478 15Y.0000000060.
24. Mao F, Wang M, Wang J, Xu WR. The role of 15-LOX-1 in colitis and colitis-associated colorectal cancer. Inflamm Res 2015; 64: 661-669.
25. Fernandes JV, Cobucci RN, Jatoba CA, de Medeiros FT, de Azevedo JW, de Araujo JM. The role of the mediators of inflammation in cancer development. Pathol Oncol Res 2015; 21: 527-534.
26. Jiang Y, Gao Q, Wang L, Guo C, Zhu F, Wang B et al. Deficiency of programmed cell death 4 results in increased IL-10 expression by macrophages and thereby attenuates atherosclerosis in hyperlipidemic mice. Cell Mol Immunol 2015; e-pub ahead of print 13 July 2015; doi:10.1038/cmi.2015.47.
27. Hilliard A, Hilliard B, Zheng SJ, Sun H, Miwa T, Song W et al. Translational regulation of autoimmune inflammation and lymphoma genesis by programmed cell death 4. J Immunol 2006; 177: 8095-8102.
28. Gallagher SJ, Mijatov B, Gunatilake D, Gowrishankar K, Tiffen J, James W et al. Control of NF-kB activity in human melanoma by bromodomain and extra-terminal protein inhibitor I-BET151. Pigment Cell Melanoma Res 2014; 27: 1126-1137.
29. Wienerroither S, Rauch I, Rosebrock F, Jamieson AM, Bradner J, Muhar M et al. Regulation of NO synthesis, local inflammation, and innate immunity to pathogens by BET family proteins. Mol Cell Biol 2014; 34: 415-427.
30. Park BS, Song DH, Kim HM, Choi BS, Lee H, Lee JO. The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature 2009; 458: 1191-1195.
31. Sun H, Gulbagci NT, Taneja R. Analysis of growth properties and cell cycle regulation using mouse embryonic fibroblast cells. Methods Mol Biol 2007; 383: 311-319.
32. Fleischer V, Sieber J, Fleischer SJ, Shock A, Heine G, Daridon C et al. Epratuzumab inhibits the production of the proinflammatory cytokines IL-6 and TNF-alpha, but not the regulatory cytokine IL-10, by B cells from healthy donors and SLE patients. Arthritis Res Ther 2015; 17: 185.
33. Yamaguchi Y, Hihara J, Hironaka K, Ohshita A, Okita R, Okawaki M et al. Postoperative immunosuppression cascade and immunotherapy using lymphokine-activated killer cells for patients with esophageal cancer: possible application for compensatory anti-inflammatory response syndrome. Oncol Rep 2006; 15: 895-901.
34. Baker BJ, Park KW, Qin H, Ma X, Benveniste EN. IL-27 inhibits OSM-mediated TNF-alpha and iNOS gene expression in microglia. Glia 2010; 58: 1082-1093.
35. Lu W, Xu Y, Shao X, Gao F, Li Y, Hu J et al. Uric acid produces an inflammatory response through activation of NF-kappaB in the hypothalamus: implications for the pathogenesis of metabolic disorders. Sci Rep 2015; 5: 12144.
36. Schuliga M. NF-kappaB signaling in chronic inflammatory airway disease. Biomolecules 2015; 5: 1266-1283.
37. Berdyshev AG, Kosiakova HV, Onopchenko OV, Panchuk RR, Stoika RS, Hula NM. N-Stearoylethanolamine suppresses the proinflammatory cytokines production by inhibition of NF-kappaB translocation. Prostaglandins Other Lipid Mediat 2015; 121: 91-96.
38. Jian CX, Li MZ, Zheng WY, He Y, Ren Y, Wu ZM et al. Tormentic acid inhibits LPS-induced inflammatory response in human gingival fibroblasts via inhibition of TLR4-mediated NF-kappaB and MAPK signalling pathway. Arch Oral Biol 2015; 60: 1327-1332.
39. Russell JA. Management of sepsis. N Engl J Med 2006; 355: 1699-1713.
40. Collins T, Cybulsky MI. NF-kappaB: pivotal mediator or innocent bystander in atherogenesis? J Clin Invest 2001; 107: 255-264.
41. Chen F. Is NF-kappaB a culprit in type 2 diabetes? Biochem Biophys Res Commun 2005; 332: 1-3.
42. Karin M, Cao Y, Greten FR, Li ZW. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002; 2: 301-310.
43. Zhang DK, Cheng LN, Huang XL, Shi W, Xiang JY, Gan HT. Tetrandrine ameliorates dextran-sulfate-sodium-induced colitis in mice through inhibition of nuclear factor-kappaB activation. Int J Colorectal Dis 2009; 24: 5-12.
44. Tai EK, Wu WK, Wong HP, Lam EK, Yu L, Cho CH. A new role for cathelicidin in ulcerative colitis in mice. Exp Biol Med (Maywood) 2007; 232: 799-808.
45. Vieira EL, Leonel AJ, Sad AP, Beltrao NR, Costa TF, Ferreira TM et al. Oral administration of sodium butyrate attenuates inflammation and mucosal lesion in experimental acute ulcerative colitis. J Nutr Biochem 2012; 23: 430-436.
46. Koon HW, Shih DQ, Chen J, Bakirtzi K, Hing TC, Law I et al. Cathelicidin signaling via the Toll-like receptor protects against colitis in mice. Gastroenterology 2011; 141: 1852-63.e1-3.
47. Zhang H, Porro G, Orzech N, Mullen B, Liu M, Slutsky AS. Neutrophil defensins mediate acute inflammatory response and lung dysfunction in dose-related fashion. Am J Physiol Lung Cell Mol Physiol 2001; 280: L947-L954.
48. Jiang Y, Yang D, Li W, Wang B, Jiang Z, Li M. Antiviral activity of recombinant mouse beta-defensin 3 against influenza A virus in vitro and in vivo. Antivir Chem Chemother 2012; 22: 255-262.
49. Rivas-Santiago B, Rivas SC, Castaneda-Delgado JE, Leon-Contreras JC, Hancock RE, Hernandez-Pando R. Activity of LL-37, CRAMP and antimicrobial peptide-derived compounds E2, E6 and CP26 against Mycobacterium tuberculosis. Int J Antimicrob Agents 2013; 41: 143-148.
50. Schlusselhuber M, Torelli R, Martini C, Leippe M, Cattoir V, Leclercq R et al. The equine antimicrobial peptide eCATH1 is effective against the facultative intracellular pathogen Rhodococcus equi in mice. Antimicrob Agents Chemother 2013; 57: 4615-4621.
51. Hibi T, Inoue N, Ogata H, Naganuma M. Introduction and overview: recent advances in the immunotherapy of inflammatory bowel disease. J Gastroenterol 2003; 38(Suppl 15): 36-42.
52. Polgar A, Brozik M, Toth S, Holub M, Hegyi K, Kadar A et al. Soluble interleukin-6 receptor in plasma and in lymphocyte culture supernatants of healthy individuals and patients with systemic lupus erythematosus and rheumatoid arthritis. Med Sci Monit 2000; 6: 13-18.
53. van Deventer SJ. [Immunology in medical practice. IV. Inflammatory bowel diseases: pathogenic starting points for specific therapy]. Ned Tijdschr Geneeskd 1997; 141: 1956-1959.
54. Hyams JS, Lerer T, Griffiths A, Pfefferkorn M, Kugathasan S, Evans J et al. Long-term outcome of maintenance infliximab therapy in children with Crohn's disease. Inflamm Bowel Dis 2009; 15: 816-822.